Basic Information | Post buying leads | Suppliers | Cas Database |
Name |
Flumazenil |
EINECS | 616-650-9 |
CAS No. | 78755-81-4 | Density | 1.39 g/cm3 |
PSA | 64.43000 | LogP | 1.71160 |
Solubility | 128 mg/L in water | Melting Point |
201-203 °C |
Formula | C15H14FN3O3 | Boiling Point | 528 °C at 760 mmHg |
Molecular Weight | 303.293 | Flash Point | 273.1 °C |
Transport Information | N/A | Appearance | Colourless crystals |
Safety | 26-27-36/37/39 | Risk Codes | 36/37/38 |
Molecular Structure | Hazard Symbols | Xi | |
Synonyms |
Anexate;Flumazepil;Flumazenil [USAN:BAN:INN];Romazicon;Flumazenilum [Latin];Flumazenil (JAN/USP);Romazicon (TN);4H-Imidazo[1,5-a][1,4]benzodiazepine-3- carboxylic acid,8-fluoro-5,6-dihydro-5- methyl-6-oxo-,ethyl ester;Flumazenilo;Lanexat;Ethyl 8-fluoro-5-methyl-5,6-dihydro-6-oxo-4H-imidazo(1,5-a)(1,4)benzodiazepine-3-carboxylate;4H-Imidazo(1,5-a)(1,4)benzodiazepine-3-carboxylic acid, 8-fluoro-5,6-dihydro-5-methyl-6-oxo-, ethyl ester;Ethyl 8-fluoro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo(1,5-a)(1,4)benzodiazepine-3-carboxylate; |
Article Data | 12 |
(E)-(dimethylamino-methyleneamino)-acetic acid ethyl ester
2-chloro-7-fluoro-4-methyl-3,4-dihydrobenzo[e][1,4]diazepin-5-one
flumazenil
Conditions | Yield |
---|---|
Stage #1: (E)-(dimethylamino-methyleneamino)-acetic acid ethyl ester With lithium hexamethyldisilazane In tetrahydrofuran at -35℃; for 1.5h; Stage #2: 2-chloro-7-fluoro-4-methyl-3,4-dihydrobenzo[e][1,4]diazepin-5-one With Dimethyl-p-toluidine In tetrahydrofuran at -40 - -35℃; for 3h; Stage #3: With acetic acid In tetrahydrofuran for 6h; pH=5 - 7; Heating; | 98% |
ethyl 2-cyanoacetate
2-chloro-7-fluoro-4-methyl-3,4-dihydrobenzo[e][1,4]diazepin-5-one
flumazenil
Conditions | Yield |
---|---|
With N,N-dimethyl-aniline; N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 0 - 20℃; for 12h; Reagent/catalyst; Solvent; | 61.3% |
8-amino-5,6-dihydro-5-methyl-6-oxo-4H-imidazol[1,5-a][1,4]benzodiazepine-3-carboxylic acid ethyl ester
flumazenil
Conditions | Yield |
---|---|
With pyridine; hydrogen fluoride; sodium nitrite at 20 - 120℃; for 2.5h; | 51% |
Multi-step reaction with 2 steps 1: BF3*Et2O; t-butyl nitrite / CH2Cl2 / -15 - 5 °C 2: 160 mg / 0.67 h / 130 °C View Scheme |
Ethyl isocyanoacetate
7-fluoro-3,4-dihydro-4-methyl-2H-1,4-benzodiazepine-2,5(1H)-dione
flumazenil
Conditions | Yield |
---|---|
Multistep reaction; |
A
flumazenil
Conditions | Yield |
---|---|
With acetic acid In tetrahydrofuran pH=5; Heating; |
flumazenil
Conditions | Yield |
---|---|
at 130℃; for 0.666667h; Balz-Schiemann reaction; | 160 mg |
Ethyl isocyanoacetate
flumazenil
Conditions | Yield |
---|---|
Multi-step reaction with 4 steps 1: 1.79 g / sodium hydride / dimethylformamide; tetrahydrofuran / 18 h 2: 97 percent / H2 / Pd/C / tetrahydrofuran; ethanol / 2 h 3: BF3*Et2O; t-butyl nitrite / CH2Cl2 / -15 - 5 °C 4: 160 mg / 0.67 h / 130 °C View Scheme | |
Multi-step reaction with 3 steps 1: N-methyl-acetamide; water; acetic acid; ethyl acetate 2: potassium carbonate / ethanol; water; trifluoroacetic acid 3: N-methyl-acetamide; water View Scheme |
7-nitro-3,4-dihydro-4-methyl-2H-1,4-benzodiazepine-2,5-(1H)-dione
flumazenil
Conditions | Yield |
---|---|
Multi-step reaction with 5 steps 1: sodium hydride; diethyl chlorophosphate / tetrahydrofuran; dimethylformamide / 0.5 h / 0 °C 2: 1.79 g / sodium hydride / dimethylformamide; tetrahydrofuran / 18 h 3: 97 percent / H2 / Pd/C / tetrahydrofuran; ethanol / 2 h 4: BF3*Et2O; t-butyl nitrite / CH2Cl2 / -15 - 5 °C 5: 160 mg / 0.67 h / 130 °C View Scheme |
8-nitro-5,6-dihydro-5-methyl-6-oxo-4H-imidazol[1,5-a][1,4]benzodiazepine-3-carboxylic acid ethyl ester
flumazenil
Conditions | Yield |
---|---|
Multi-step reaction with 3 steps 1: 97 percent / H2 / Pd/C / tetrahydrofuran; ethanol / 2 h 2: BF3*Et2O; t-butyl nitrite / CH2Cl2 / -15 - 5 °C 3: 160 mg / 0.67 h / 130 °C View Scheme |
flumazenil
Conditions | Yield |
---|---|
Multi-step reaction with 4 steps 1: 1.79 g / sodium hydride / dimethylformamide; tetrahydrofuran / 18 h 2: 97 percent / H2 / Pd/C / tetrahydrofuran; ethanol / 2 h 3: BF3*Et2O; t-butyl nitrite / CH2Cl2 / -15 - 5 °C 4: 160 mg / 0.67 h / 130 °C View Scheme |
Flumazenil, with the CAS NO.78755-81-4, has the IUPAC Name of Ethyl 8-fluoro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate. Synonyms of it are 4H-Imidazo(1,5-a)(1,4)benzodiazepine-3-carboxylic acid, 8-fluoro-5,6-dihydro-5-methyl-6-oxo-, ethyl ester; 4H-Imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic acid, 8-fluoro-5,6-dihydro-5-methyl-6-oxo-, ethyl ester; 8-Fluoro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic acid ethyl ester; 8-Fluoro-5-méthyl-6-oxo-5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazépine-3-carboxylate d'éthyle. It is a benzodiazepine receptor antagonist available for injection only, and the only benzodiazepine receptor antagonist on the market today.
Physical properties about Flumazenil are: (1)ACD/LogP: 2.151; (2)ACD/LogD (pH 5.5): 2.15; (3)ACD/LogD (pH 7.4): 2.15; (4)ACD/BCF (pH 5.5): 25.41; (5)ACD/BCF (pH 7.4): 25.41; (6)ACD/KOC (pH 5.5): 352.59; (7)ACD/KOC (pH 7.4): 352.60; (8)#H bond acceptors: 6; (9)#Freely Rotating Bonds: 3; (10)Index of Refraction: 1.634 ; (11)Molar Refractivity: 77.586 cm3; (12)Molar Volume: 217.075 cm3; (13)Polarizability: 30.757 10-24cm3; (14)Surface Tension: 48.4690017700195 dyne/cm; (15)Density: 1.397 g/cm3; (16)Flash Point: 273.115 °C; (17)Enthalpy of Vaporization: 80.269 kJ/mol; (18)Boiling Point: 527.983 °C at 760 mmHg
Uses of Flumazenil: Flumazenil is used to against the sedative effect and disorientation after use of overdose of benzodiazepine drugs leather, and has anticonvulsant activity and antiepileptic effect. It can also be used after the recovery period and encephalopathy due to cirrhosis of the liver due to alcoholism, unexplained loss of consciousness diagnostic medicine. Besides it is also used to identify the benzodiazepine class and other drug intoxication or brain damage. It is still used as central nervous system stimulant.
When you are using this chemical, please be cautious about it as the following:
1. In case of contact with eyes, rinse immediately with plenty of water and seek medical advice;
2. Take off immediately all contaminated clothing;
3. Wear suitable protective clothing, gloves and eye/face protection;
You can still convert the following datas into molecular structure:
(1)InChI=1S/C15H14FN3O3/c1-3-22-15(21)13-12-7-18(2)14(20)10-6-9(16)4-5-11(10)19(12)8-17-13/h4-6,8H,3,7H2,1-2H3;
(2)InChIKey=OFBIFZUFASYYRE-UHFFFAOYSA-N;
(3)Smilesn12c3c(C(=O)N(Cc1c(nc2)C(=O)OCC)C)cc(cc3)F
The toxicity data is as follows:
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
dog | LDLo | intravenous | > 30mg/kg (30mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 23, Pg. 201, 1992. | |
dog | LDLo | oral | > 640mg/kg (640mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 23, Pg. 201, 1992. | |
man | LDLo | intravenous | 5700ng/kg/C (.0057mg/kg) | CARDIAC: CARDIOMYOPATHY INCLUDING INFARCTION CARDIAC: ARRHYTHMIAS (INCLUDING CHANGES IN CONDUCTION) CARDIAC: CHANGE IN RATE | British Medical Journal. Vol. 304, Pg. 1415, 1992. |
mouse | LD50 | intraperitoneal | 4gm/kg (4000mg/kg) | Drugs of the Future. Vol. 7, Pg. 402, 1982. | |
mouse | LD50 | intravenous | 143mg/kg (143mg/kg) | BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD BEHAVIORAL: REGIDITY | Journal de Toxicologie Clinique et Experimentale. Vol. 7, Pg. 223, 1987. |
mouse | LD50 | oral | 1300mg/kg (1300mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: REGIDITY BEHAVIORAL: TREMOR | Journal de Toxicologie Clinique et Experimentale. Vol. 7, Pg. 223, 1987. |
mouse | LDLo | subcutaneous | > 1gm/kg (1000mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 23, Pg. 201, 1992. | |
rabbit | LD50 | oral | 2gm/kg (2000mg/kg) | BEHAVIORAL: TREMOR BEHAVIORAL: REGIDITY BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) | Journal de Toxicologie Clinique et Experimentale. Vol. 7, Pg. 223, 1987. |
rat | LD50 | intraperitoneal | 1360mg/kg (1360mg/kg) | Drugs of the Future. Vol. 7, Pg. 402, 1982. | |
rat | LD50 | intravenous | 85mg/kg (85mg/kg) | BEHAVIORAL: REGIDITY BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD | Journal de Toxicologie Clinique et Experimentale. Vol. 7, Pg. 223, 1987. |
rat | LD50 | oral | 4200mg/kg (4200mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: REGIDITY BEHAVIORAL: TREMOR | Journal de Toxicologie Clinique et Experimentale. Vol. 7, Pg. 223, 1987. |
women | TDLo | intravenous | 4ug/kg (.004mg/kg) | CARDIAC: EKG CHANGES NOT DIAGNOSTIC OF ABOVE CARDIAC: PULSE RATE INCREASE WITHOUT FALL IN BP BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD | Pediatric Emergency Care. Vol. 11, Pg. 186, 1995. |
women | TDLo | oral | 2mg/kg/2D-I (2mg/kg) | BEHAVIORAL: EXCITEMENT BEHAVIORAL: AGGRESSION BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS" | Lancet. Vol. 339, Pg. 488, 1992. |